LANGHORNE, PA — NEXGEL Inc. (NASDAQ: NXGL) announced it has signed a definitive agreement to license and acquire a portfolio of regenerative biomaterial products from Celularity Inc. (NASDAQ: CELU), a transaction the company said is expected to expand its product offerings and increase revenue.
The company said the acquisition includes six commercial-stage regenerative biomaterial products used in tendon repair, skin grafts, and bone growth.
NEXGEL said the transaction is expected to increase its annual revenue to approximately $35 million and make the company profitable upon closing.
The company also said an experienced commercial and scientific team associated with the portfolio is expected to join NEXGEL, expanding its sales and operational capabilities.
The products included in the transaction have more than a decade of clinical use and existing insurance reimbursement pathways, according to the company.
NEXGEL said three additional products are planned for regulatory filings with the U.S. Food and Drug Administration through the 510(k) pathway in 2026, 2027, and 2028.
Adam Levy, chief executive officer of NEXGEL, said the acquisition is intended to expand the company’s position in regenerative biomaterials.
“We are acquiring a profitable, revenue-generating regenerative biomaterials platform — along with the team behind it — that will approximately triple our revenue and reposition NEXGEL in the medical technology market,” Levy said.
The transaction is subject to customary closing conditions and financing.
NEXGEL said it expects to complete approximately $14.9 million in additional financing in the first quarter of 2026 or early in the second quarter, following a previously announced financing of about $1.8 million.
Additional details about the transaction will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission and made available through the SEC’s EDGAR database.
Palladium Capital Group LLC served as the placement agent for the financing transaction.
NEXGEL, based in Langhorne, Pennsylvania, develops and manufactures hydrogel-based products used in healthcare, beauty, and consumer applications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.